Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
Antidepressant Drugs: Overview01:25

Antidepressant Drugs: Overview

Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs01:28

Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs

Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
Electroconvulsive Therapy01:30

Electroconvulsive Therapy

Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early years,...
Depressive Disorders: MDD and Dysthymia01:27

Depressive Disorders: MDD and Dysthymia

Depressive disorders are a group of mental health conditions characterized by pervasive feelings of sadness, diminished pleasure in life, and a significant impact on daily functioning. These conditions are most prevalent in individuals during their 30s and affect women at twice the rate of men. Contrary to popular belief, younger individuals are generally more susceptible to these disorders than older adults. Two key types of depressive disorders include Major Depressive Disorder (MDD) and...
Drug Therapy01:28

Drug Therapy

The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Gamma auditory steady-state response and remission in antipsychotic-naïve patients at clinical high risk for psychosis: a longitudinal study.

The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry·2026
Same author

Cortico-cortical paired associative stimulation increases SMA-M1 facilitation in tremor-dominant Parkinson's disease.

Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology·2026
Same author

Stress and synaptic density in psychosis and clinical high risk: evidence from [<sup>18</sup>F]SynVesT-1 PET.

Translational psychiatry·2026
Same author

Local chemoarchitecture explains widespread lower cortical thickness associated with clinical high risk for psychosis.

Molecular psychiatry·2026
Same author

Correction: "Ask" or "Inquire": operationalizing speech formality in psychosis and its risk states using etymology.

NPP - digital psychiatry and neuroscience·2025
Same author

Glutamate, NAA, and energy metabolism in clinical high risk and first episode psychosis.

Scientific reports·2025
Same journal

Pharmacotherapeutic interventions for pediatric ulcerative colitis.

Expert opinion on pharmacotherapy·2026
Same journal

The rise and fall of TRPV1-targeted analgesia in osteoarthritis: a critical appraisal.

Expert opinion on pharmacotherapy·2026
Same journal

Dopamine transporter and beyond: evolving targets and combination strategies in stimulant use disorder.

Expert opinion on pharmacotherapy·2026
Same journal

GnRH antagonists for the treatment of fibroids and adenomyosis, current evidence and future perspectives.

Expert opinion on pharmacotherapy·2026
Same journal

Pharmacotherapeutic strategies for the management of congenital adrenal hyperplasia.

Expert opinion on pharmacotherapy·2026
Same journal

Current advances in pharmacotherapeutic strategies for the treatment of complicated intra-abdominal infections.

Expert opinion on pharmacotherapy·2026
See all related articles

Related Experiment Video

Updated: Jul 5, 2026

Effect of Yi-Nao-Jie-Yu Prescription on Post-Stroke Depression in Rats using Middle Cerebral Artery Occlusion Combined with Behavioral Restraint
06:45

Effect of Yi-Nao-Jie-Yu Prescription on Post-Stroke Depression in Rats using Middle Cerebral Artery Occlusion Combined with Behavioral Restraint

Published on: January 9, 2026

Antidepressant therapy in post-stroke depression.

Sergio E Starkstein1, Romina Mizrahi, Brian D Power

  • 1University of Western Australia, School of Psychiatry and Clinical Neurosciences, Australia. ses@cyllene.uwa.edu.au

Expert Opinion on Pharmacotherapy
|May 14, 2008
PubMed
Summary
This summary is machine-generated.

Post-stroke depression (PSD) affects 40% of stroke survivors and worsens outcomes. Antidepressants like sertraline, citalopram, and nortriptyline are effective treatments for established PSD.

More Related Videos

A Middle Cerebral Artery Occlusion Technique for Inducing Post-stroke Depression in Rats
04:38

A Middle Cerebral Artery Occlusion Technique for Inducing Post-stroke Depression in Rats

Published on: May 22, 2019

Related Experiment Videos

Last Updated: Jul 5, 2026

Effect of Yi-Nao-Jie-Yu Prescription on Post-Stroke Depression in Rats using Middle Cerebral Artery Occlusion Combined with Behavioral Restraint
06:45

Effect of Yi-Nao-Jie-Yu Prescription on Post-Stroke Depression in Rats using Middle Cerebral Artery Occlusion Combined with Behavioral Restraint

Published on: January 9, 2026

A Middle Cerebral Artery Occlusion Technique for Inducing Post-stroke Depression in Rats
04:38

A Middle Cerebral Artery Occlusion Technique for Inducing Post-stroke Depression in Rats

Published on: May 22, 2019

Area of Science:

  • Neurology
  • Psychiatry
  • Clinical Medicine

Background:

  • Post-stroke depression (PSD) affects approximately 40% of stroke survivors.
  • PSD is linked to poorer prognosis, including functional deficits, cognitive impairment, and increased mortality.

Purpose of the Study:

  • To review controlled treatment trials for post-stroke depression (PSD).

Main Methods:

  • An unsystematic review of recent studies investigating PSD treatments.
  • Focus on controlled trials evaluating therapeutic interventions.

Main Results:

  • Randomized controlled trials confirm the efficacy of sertraline, citalopram, and nortriptyline for treating PSD.
  • Further research is needed to determine if antidepressants can prevent PSD or reduce mortality.

Conclusions:

  • Established PSD can be effectively treated with specific antidepressant medications.
  • The preventative role of antidepressants and their impact on mortality require additional investigation.